Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2)

被引:165
作者
Otten, RA
Smith, DK
Adams, DR
Pullium, JK
Jackson, E
Kim, CN
Jaffe, H
Janssen, R
Butera, S
Folks, TM
机构
[1] Ctr Dis Control, HARB, DASTLR, NCID, Atlanta, GA 30333 USA
[2] Ctr Dis Control & Prevent, Sci Resources Program, Natl Ctr Infect Dis, NCID, Atlanta, GA 30333 USA
[3] Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA
[4] Emory Univ, Div Anim Resources, Atlanta, GA 30332 USA
关键词
D O I
10.1128/JVI.74.20.9771-9775.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Postexposure prophylaxis (PEP) after intravaginal exposure to human immunodeficiency virus (HIV) was investigated using the HN type 2 (HIV-2)/pig-tailed macaque transmission model. PEP for 28 days with the reverse transcriptase inhibitor (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA; tenofovir) was initiated 12 to 72 h following HIV-2 exposure. Systemic infection was not evident in the 12- and 36-h groups, as defined by plasma viremia, cell-associated provirus, antibody responses, and lymph node virus. Breakthrough infection in the 72-h group was detected at week 16 post-virus exposure. These results demonstrate for the first time using a vaginal transmission model that early intervention after high-risk sexual exposures may prevent infection.
引用
收藏
页码:9771 / 9775
页数:5
相关论文
共 25 条
  • [1] [Anonymous], 1998, MMWR Recomm Rep, V47, P1
  • [2] Black Roberta J., 1997, American Journal of Medicine, V102, P39, DOI 10.1016/S0002-9343(97)00059-4
  • [3] A case-control study of HIV seroconversion in health care workers after percutaneous exposure
    Cardo, DM
    Culver, DH
    Ciesielski, CA
    Srivastava, PU
    Marcus, R
    Abiteboul, D
    Heptonstall, J
    Ippolito, G
    Lot, F
    McKibben, P
    Bell, DM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (21) : 1485 - 1490
  • [4] *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P929
  • [5] Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use
    Katz, MH
    Gerberding, JL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) : 1097 - 1100
  • [6] A PARTIALLY ATTENUATED SIMIAN IMMUNODEFICIENCY VIRUS INDUCES HOST IMMUNITY THAT CORRELATES WITH RESISTANCE TO PATHOGENIC VIRUS CHALLENGE
    LOHMAN, BL
    MCCHESNEY, MB
    MILLER, CJ
    MCGOWAN, E
    JOYE, SM
    VANROMPAY, KKA
    REAY, E
    ANTIPA, L
    PEDERSEN, NC
    MARTHAS, ML
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (11) : 7021 - 7029
  • [7] A minimally replicative HIV-2 live-virus vaccine protects M-nemestrina from disease after HIV-2287 challenge
    Looney, DJ
    McClure, J
    Kent, SJ
    Radaelli, A
    Kraus, G
    Schmidt, A
    Steffy, K
    Greenberg, P
    Hu, SL
    Morton, WR
    Wong-Staal, F
    [J]. VIROLOGY, 1998, 242 (01) : 150 - 160
  • [8] Postexposure prophylaxis after nonoccupational HIV exposure - Clinical, ethical, and policy considerations
    Lurie, P
    Miller, S
    Hecht, F
    Chesney, M
    Lo, B
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (20): : 1769 - 1773
  • [9] MASTRO TD, 1996, AIDS SA, V10, P575
  • [10] MERTENS TE, 1994, AIDS S1, V8, pS361